Shares of Nuformix plc (LON:NFX – Get Free Report) were down 15.8% during trading on Wednesday . The company traded as low as GBX 0.08 ($0.00) and last traded at GBX 0.08 ($0.00). Approximately 21,459,072 shares changed hands during mid-day trading, a decline of 69% from the average daily volume of 69,130,867 shares. The stock had previously closed at GBX 0.10 ($0.00).
Nuformix Stock Down 15.8 %
The company has a 50 day simple moving average of GBX 0.07 and a 200 day simple moving average of GBX 0.08. The stock has a market cap of £985,447.27, a price-to-earnings ratio of -2.43 and a beta of 1.22.
Nuformix (LON:NFX – Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- Comparing and Trading High PE Ratio Stocks
- Buffett’s on the Sidelines – Should You Follow?
- Stock Market Sectors: What Are They and How Many Are There?
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- There Are Different Types of Stock To Invest In
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
